valsartan has been researched along with tak 491 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, GL; Cao, C; Kupfer, S; Perez, A; Sica, D; Weber, MA; White, WB | 1 |
| Ho, C; Kajiya, T; Kurtz, TW; Vilardi, R; Wang, J | 1 |
| Bakris, GL; Cuadra, RH; Kupfer, S; Lloyd, E; White, WB | 1 |
| Du, X; Hisada, M; Li, Z; Long, M; Lv, Q; Ma, C; Tang, C; Wu, J; Xia, Y; Yao, Z; Zhang, J; Zheng, Z; Zhou, W | 1 |
3 trial(s) available for valsartan and tak 491
| Article | Year |
|---|---|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Oxadiazoles; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Middle Aged; Oxadiazoles; Prediabetic State; Tetrazoles; Valsartan | 2016 |
A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; China; Dose-Response Relationship, Drug; Double-Blind Method; Essential Hypertension; Female; Humans; Male; Middle Aged; Oxadiazoles; Treatment Outcome; Valsartan | 2020 |
1 other study(ies) available for valsartan and tak 491
| Article | Year |
|---|---|
Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
Topics: 3T3 Cells; Adipocytes; Adipogenesis; Adiponectin; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biomarkers; Cell Differentiation; Cell Proliferation; Complement Factor D; Gene Expression; Leptin; Mice; Oxadiazoles; PPAR alpha; PPAR delta; Tetrazoles; Valine; Valsartan | 2011 |